Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine Extension Study in Pediatric MDD
NCT02871297Phase 3Terminated
- Sponsor
- Lundbeck
- Start
- Aug 2016
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoint: Treatment-Emergent Adverse Events. Started Aug 2016; status: terminated.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02871297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871297.